Stryker Corporation $SYK Stock Position Increased by Capital Advisors Inc. OK

Capital Advisors Inc. OK raised its position in shares of Stryker Corporation (NYSE:SYK) by 14.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 205,253 shares of the medical technology company’s stock after purchasing an additional 25,767 shares during the period. Capital Advisors Inc. OK owned 0.05% of Stryker worth $64,622,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Stryker by 21.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after purchasing an additional 481,175 shares during the period. New Mexico Educational Retirement Board grew its holdings in Stryker by 7.5% in the 2nd quarter. New Mexico Educational Retirement Board now owns 17,109 shares of the medical technology company’s stock worth $5,387,000 after buying an additional 1,200 shares in the last quarter. Mufg Securities Americas Inc. increased its position in Stryker by 9.0% in the 2nd quarter. Mufg Securities Americas Inc. now owns 10,392 shares of the medical technology company’s stock valued at $3,272,000 after acquiring an additional 862 shares during the period. Van ECK Associates Corp increased its position in Stryker by 7.6% in the 2nd quarter. Van ECK Associates Corp now owns 22,011 shares of the medical technology company’s stock valued at $6,930,000 after acquiring an additional 1,555 shares during the period. Finally, Ferguson Wellman Capital Management Inc. raised its stake in Stryker by 1.2% during the 2nd quarter. Ferguson Wellman Capital Management Inc. now owns 186,935 shares of the medical technology company’s stock valued at $58,855,000 after acquiring an additional 2,180 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. BTIG Research decreased their price target on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Evercore set a $350.00 price objective on shares of Stryker in a research note on Monday, July 6th. UBS Group began coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective for the company. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Wolfe Research cut shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Stock Up 2.9%

Shares of SYK stock opened at $331.32 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The business’s fifty day moving average is $329.10 and its 200-day moving average is $331.47. The stock has a market cap of $127.08 billion, a PE ratio of 34.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is currently 36.48%.

Insider Buying and Selling

In other Stryker news, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.